Go to:
Logótipo
Comuta visibilidade da coluna esquerda
Você está em: Start > Publications > View > Hidradenitis Suppurativa in Children Treated with Finasteride-A Case Series
Publication

Publications

Hidradenitis Suppurativa in Children Treated with Finasteride-A Case Series

Title
Hidradenitis Suppurativa in Children Treated with Finasteride-A Case Series
Type
Article in International Scientific Journal
Year
2017
Authors
Mota, F
(Author)
Other
The person does not belong to the institution. The person does not belong to the institution. The person does not belong to the institution. Without AUTHENTICUS Without ORCID
Machado, S
(Author)
Other
The person does not belong to the institution. The person does not belong to the institution. The person does not belong to the institution. Without AUTHENTICUS Without ORCID
Selores, M
(Author)
Other
The person does not belong to the institution. The person does not belong to the institution. The person does not belong to the institution. Without AUTHENTICUS Without ORCID
Journal
Title: Pediatric DermatologyImported from Authenticus Search for Journal Publications
Vol. 34
Pages: 578-583
ISSN: 0736-8046
Publisher: Wiley-Blackwell
Other information
Authenticus ID: P-00N-0TX
Abstract (EN): Background: Hidradenitis suppurativa (HS) is rare in childhood, with only 2% of cases in patients younger than 11 years. It is a chronic, recurrent, debilitating condition for which no universally effective treatment has been developed. We present five cases of children with HS diagnosed between the ages of 6 and 11 years. Methods: Patients were treated with oral finasteride 1 to 5 mg/day. All had entered puberty at the time of treatment initiation. All had normal laboratory results before starting treatment. The maximum duration of treatment was 24 months. Results: Four patients were female. Two were overweight. Three had been previously treated with oral antibiotics, and two of these with oral isotretinoin, with partial or no improvement. Overall improvement of the disease was observed in all patients, with a reduction of the frequency and intensity of the flares. No adverse effects were observed or reported during treatment. Conclusion: Treatment of HS can be challenging. The options available include antimicrobials, immunosuppressants, hormonal therapies, lasers, and surgery. The authors report the largest series of children with HS treated with finasteride. The results support the use of finasteride as monotherapy for the treatment of this disease in children. Further studies are necessary to fully understand the role of this drug in the management of this disease.
Language: English
Type (Professor's evaluation): Scientific
No. of pages: 6
Documents
We could not find any documents associated to the publication.
Related Publications

Of the same journal

Anogenital warts in children: Analysis of a cohort of 34 prepubertal children (2018)
Another Publication in an International Scientific Journal
Costa Silva, M; Azevedo, F; Carmen Silva
An infant with a tumor on the maxillary gingiva (2011)
Another Publication in an International Scientific Journal
de almeida leite, fs; pereira, j; amaral, m; furtado, a; correia, a; de sousa, p
Tuberculosis in a child presenting as asymptomatic oropharyngeal and laryngeal lesions (2003)
Article in International Scientific Journal
magina, s; Carmen Silva; Resende, C; Azevedo, F; Amado, F; Cardoso, V; Almeida, F; Mesquita Guimaraes, J
Primary cutaneous alveolar rhabdomyosarcoma in an adolescent - A challenging diagnosis (2020)
Article in International Scientific Journal
Calvao, J; Cardoso, JC; Ramos, L; Figueiredo, A
Linear Lupus Erythematosus Profundus as an Initial Manifestation of Systemic Lupus Erythematosus in a Child (2014)
Article in International Scientific Journal
Fernandes, S; Santos, S; Freitas, I; Salgado, M; Afonso, A; Cardoso, J

See all (7)

Recommend this page Top
Copyright 1996-2025 © Faculdade de Direito da Universidade do Porto  I Terms and Conditions  I Acessibility  I Index A-Z
Page created on: 2025-07-14 at 09:45:07 | Privacy Policy | Personal Data Protection Policy | Whistleblowing